Fig 1: The expression level of Bcl-2?c-myc and bax protein after treatment with Lxn in CD133+ cells. (A) The expression level of Bcl-2?c-myc and bax protein by Western blot analysis. (B) The relative expression level of Bcl-2?bax?bcl-2/bax and c-myc protein compared to the controls. a P < 0.05, b P < 0.05, c P < 0.05, d P < 0.05.
Fig 2: Cytotoxic effects of Lxn treatment in CD133+ miapaca-2 cells treated with Lxn at various concentrations of Lxn. The inhibitory ratio was calculated according to the following formula: Inhibitory ratio = (OD450 nm value of control group - OD450 nm value of Lxn treatment group)/(OD450 nm value of control group - OD450 nm value of blank group). a P < 0.05, b P < 0.05, c P < 0.05, d P < 0.05.
Fig 3: Cell death analysis in CD133+ and CD133- cells. (A-D) Apoptosis of CD133+ miapaca-2 cells treated with 0 ng/µL (A), 10 ng/µL (B), 20 ng/µL (C) and 40 ng/µL (D) of Lxn. The lower left indicates live cells (Annexin V-FITC negative/PI negative); the lower right shows early apoptotic cells (Annexin V-FITC positive/PI negative). The upper left shows damaged cells (Annexin V-FITC negative/PI positive), while the upper right demonstrates necrotic cells and late apoptotic cells (Annexin V-FITC positive/PI positive). The number represents the percentage of early apoptotic cells, necrotic cells, and late apoptotic cells in each condition (right quadrant). (E) The percentage of apoptotic cells, necrotic cells, and late apoptotic CD133+ miapaca-2 cells treated with 0 ng/µL, 5 ng/µL, 10 ng/µL, 20 ng/µL and 40 ng/µL of Lxn. a P < 0.05, b P < 0.05, c P < 0.05, d P < 0.05. FITC, fluorescein iodothiocyanate; PI, propidium bromide.
Fig 4: Lxn expression in CD133+ and CD133- cells. (A) The Lxn protein expression level was decreased in CD133+ cells compared to CD133- cells. (B) The Lxn mRNA expression level in CD133+ cells was significantly lower than that in CD133- cells. a P < 0.05.
Supplier Page from Abcam for Recombinant Human LXN/TCI protein